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A defective epinephrine response to hypoglycemia is a com-
mon disorder in type 1 diabetes. We assessed the role of the
adrenomedullary capacity to secrete epinephrine in this dis-
order by measuring plasma metanephrine levels in affected
type 1 diabetic patients comparedwith those inmatched non-
diabetic controls. Metanephrine is formed from epinephrine
that leaks fromadrenomedullary storage vesicles by catechol-
O-methyl transferase (COMT) and is continuously released
into the circulation. Thus, plasmametanephrine levels reflect
adrenomedullary epinephrine content and, provided there is
normal COMT activity, the adrenomedullary capacity to se-
crete epinephrine. Diabetic patients had approximately 25%
lower plasma metanephrine levels than controls (0.18  0.09
vs. 0.24  0.02 nmol/liter; P  0.012), whereas plasma epineph-
rine, norepinephrine, and normetanephrine levels were com-
parable between patients and controls. In response to hypo-
glycemia, the increments in plasma epinephrine and plasma
metanephrine levels were both significantly lower in diabetic
patients than in controls (P < 0.001), but the increase in
plasma metanephrine as a percentage of the increase in
plasma epinephrine was identical, indicating similar COMT
activity. We conclude that type 1 diabetic patients with an
impaired epinephrine response to hypoglycemia have lower
plasmametanephrine levels thanmatchedcontrols, reflecting
decreased adrenomedullary stores of epinephrine and indi-
cating reduced adrenomedullary capacity to secrete epineph-
rine. (J Clin Endocrinol Metab 89: 2057–2061, 2004)
HYPOGLYCEMIA IS A very common phenomenon forvirtually all patients with type 1 diabetes. The risk for
iatrogenic hypoglycemia sharply increases when an already
absent glucagon response is accompanied by failure to suf-
ficiently secrete epinephrine in response to hypoglycemia (1).
In addition, because of epinephrine’s role in the appearance
of hypoglycemic (warning) symptoms, impaired epineph-
rine responses may adversely affect the perception of hypo-
glycemia and, as such, contribute to unawareness of hypo-
glycemia. In the absence of autonomic neuropathy, it has
been proposed that the impaired epinephrine response to
hypoglycemia is caused by resetting the threshold value for
epinephrine release to a lower glucose level (2). This hy-
pothesis is based on observations that glycemic thresholds
for epinephrine release shift to lower glucose levels after
antecedent hypoglycemia (3) and after improvement of met-
abolic control (4–9), whereas they shift to higher glucose
levels when hypoglycemia is avoided (10–12) and metabolic
control is relaxed (13).
Recent observations, however, suggest that a reduced ad-
renomedullary secretory capacity contributes to the im-
paired epinephrine response. For instance, antecedent hy-
poglycemia has been found to suppress adrenergic responses
to subsequent exercise (14), and reduced adrenergic re-
sponses to exercise have been reported in well controlled
diabetic patients without autonomic neuropathy (15, 16).
Others, however, found no effect of antecedent hypoglyce-
mia on adrenergic responses to exercise (17) or reported that
the capacity to secrete epinephrine during exercise remained
unaltered in diabetic patients despite recurrent hypoglyce-
mia (18). Differences in the intensity and duration of, and the
compliance with the exercise protocols used in the various
studies may explain some of these conflicting data. In ad-
dition, exercise tests are not the most profound stimulus for
the adrenal medulla, so normal epinephrine responses can
occur despite reduced adrenomedullary secretory capacity.
The introduction of a sensitive method for measurements
of free plasma metanephrines has provided a reliable means
to estimate adrenomedullary capacity (19–21). Within the
adrenal medulla, epinephrine leaking from storage vesicles
into the cytoplasm is converted tometanephrine by catechol-
O-methyl transferase (COMT). In contrast to epinephrine,
metanephrine is continuously released into the bloodstream,
almost independently of adrenergic stimulation (22). As over
90% of circulating metanephrine has an adrenomedullary
source (23), plasma metanephrine levels reflect adrenomed-
ullary stores of epinephrine and, provided that COMT ac-
tivity is normal, the adrenomedullary capacity to secrete
epinephrine. In the present studywemeasured plasmameta-
nephrine levels to determine whether the adrenomedullary
secretory capacity is reduced in type 1 diabetic patients with
Abbreviations: COMT, Catechol-O-methyl transferase; M/E,
metanephrine/epinephrine.
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impaired epinephrine responses to hypoglycemia. We used
a hyperinsulinemic normoglycemic-hypoglycemic glucose
clamp to correct for an effect of hyperglycemia (24) and to
investigate the effect of hypoglycemia on metanephrine re-
lease in relation to epinephrine release.
Subjects and Methods
From a previous study we selected 10 patients who had an epineph-
rine response to hypoglycemia that was below the lower limit of the
normal response and 10 matched nondiabetic controls (25). All patients
used regular insulin or insulin analogs in a basal-bolus regimen or in an
sc pump. No patients had signs of autonomic neuropathy, as measured
by standard cardiovascular reflex tests (heart rate responses during deep
breathing, heart rate response to Valsalva maneuver, heart rate and
blood pressure responses to standing, and blood pressure response to
sustained handgrip) (26), and no one usedmedication other than insulin
or oral contraceptives. The study was approved by the local hospital
ethics committee, and all participants gave written informed consent.
Hyperinsulinemic clamp
Patients were instructed to reduce the evening insulin dose or noc-
turnal insulin infusions before the studies to avoid nocturnal hypogly-
cemia. Both patients and controls were admitted to the research unit at
0800 h after an overnight fast and having abstained from caffeine-
containing beverages for at least 48 h. The brachial artery of the non-
dominant arm was cannulated under local anesthesia for blood sam-
pling and blood pressure recording. The antecubital vein of the
contralateral armwas cannulated for infusion of insulin (Actrapid,Novo
Nordisk, Bagsvaerd, Denmark) and glucose. Baseline variables were
obtained after a stabilization period of 30–45 min. Thereafter, a hyper-
insulinemic (360 pmol/m2min) hypoglycemic glucose clamp proce-
dure was performed, as described previously (25). Using a variable
infusion of 20% glucose, the arterial plasma glucose concentration was
sequentially clamped at 5.0, 3.5, and 2.5 mmol/liter at hourly intervals,
guided by plasma glucose levels measured in duplicate every 5 min by
the glucose oxidationmethod (Glucose Analyzer II, Beckman, Fullerton,
CA). Arterial blood was sampled for measurements of plasma cat-
echolamines and metanephrines at baseline, during the final 30 min of
clamped normoglycemia, and during the final 30 min of the second
hypoglycemic phase (2.5 mmol/liter).
Analytical methods
Plasma epinephrine and norepinephrine were analyzed by HPLC
with fluorometric detection, as described previously (27). Plasma meta-
nephrine and normetanephrine levels were determined by HPLC and
electrochemical detection (interassay coefficient of variation of 6.4% for
metanephrine and of 6.8% for normetanephrine) (28). Plasma insulin
and C peptide were measured by RIAs (25).
Calculations and statistics
COMT activity was assessed by the followingmethods. Firstly, based
on earlier reports in rodents, metanephrine/epinephrine (M/E) ratios
were calculated for each individual participant at baseline and during
normoglycemia (24). Secondly, we calculated the absolute increase in
plasma metanephrine level above baseline as a percentage of the abso-
lute increase in plasma epinephrine level in response to hypoglycemia.
Serial data were compared by two-way ANOVA, and means were com-
pared by t test. For data that had no normal distribution, we used the
Wilcoxon signed rank test and Mann-Whitney U test to compare paired
andunpaired data, respectively. For calculations and statistical analyses,
the SPSS personal computer software package version 9.0 (SPSS, Inc.,
Chicago, IL) was used, and P  0.05 was considered statistically sig-
nificant. Results are presented as the mean  sem unless otherwise
specified.
Results
The characteristics of the participants are given in Table 1.
As expected, type 1 diabetic patients had higher hemoglobin
A1C, fasting plasma glucose and insulin levels, and lower C
peptide levels than controls (all P  0.05). At baseline, there
were no differences in arterial plasma epinephrine, norepi-
nephrine, or normetanephrine levels between patients and
controls, but plasma metanephrine levels were 25% lower in
diabetic patients than in controls (P  0.012; Table 2). As a
consequence, diabetic patients had a lower M/E ratio than
controls (0.93  0.11 vs. 1.72  0.30; P  0.034).
Normoglycemia
Plasma glucose levels obtained during the normoglycemic
phase of the clamp were similar in patients and controls
(5.0  0.0 vs. 4.9  0.1 mmol/liter; P  0.16). Plasma insulin
levels increased by similar amounts in both groups, so that
insulin levels remained somewhat higher in patients than in
controls (836 92 vs. 559 24 pmol/liter; P 0.013). During
normoglycemia, plasma epinephrine levels did not change
significantly in control or diabetic subjects. Plasma meta-
nephrine levels decreased in controls (P 0.008) and tended
to decrease in patients (P  0.10), but remained about 25%
lower in patients than in controls (P  0.019). As a conse-
quence, the M/E ratio decreased in both patients and con-
trols (both P  0.05) during normoglycemia, but remained
lower in the patients (0.58  0.07 vs. 1.08  0.12; P  0.005).
Plasma norepinephrine levels increased in both patients (P
0.007) and controls (P  0.005), whereas plasma normeta-
nephrine levels did not change in either group.
Hypoglycemia
Plasma glucose levels obtained during the hypoglycemic
phase of the clamp were 2.4 0.0 mmol/liter in the patients
and 2.5  0.0 mmol/liter in the controls (P  0.24). Hypo-
glycemia increased plasma epinephrine and metanephrine
levels in both patients and controls (all P  0.01; Table 2).
Plasma epinephrine levels increased by 52-fold in the control
and by 12-fold in the diabetic subjects (P  0.001). Plasma
metanephrine levels increased by 2.9-fold in the control sub-
jects and by 2.0-fold in the diabetic patients (P  0.001). The
absolute increase above baseline in plasma concentration of
metanephrine as a percentage of the absolute increase in
plasma concentration of epinephrine was 6.7  0.9% in con-
trol subjects and 6.7 1.5% in diabetic patients (P 0.97; Fig.





No. (M/F) 10 (5/5) 10 (5/5)
Age (yr) 32.7  10.9 32.2  8.7
BMI (kg/m2) 23.4  2.6 22.9  2.1
Duration of diabetes (yr) 15.0  6.4
HbA1c (%) 7.3  0.5
a 5.1  0.2
Fasting plasma glucose
(mmol/liter)
12.2  3.2a 5.2  0.5
C peptide (mmol/liter) 0.01a 0.40  0.14
Insulin (pmol/liter) 337  215b 65  18
Data are themean SD. To convert plasma glucose values tomg/dl,
multiply by 18; to convert plasma insulin values to U/ml, divide by
6.0. BMI, Bodymass index;DM, diabetesmellitus;HbA1c, hemoglobin
A.
a P  0.005 vs. controls.
b P  0.05 vs. controls.
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1). In response to hypoglycemia, plasma norepinephrine lev-
els increased by 2.7-fold in diabetic patients and by 4.3-fold
in controls (P  0.015), whereas plasma normetanephrine
levels increased slightly in diabetic patients and controls, but
to a similar extent (Fig. 1).
Discussion
The results of the present study indicate that type 1 dia-
betic patients with an impaired epinephrine response to hy-
poglycemia have a reduced adrenomedullary capacity to
secrete epinephrine. This conclusion is based on the finding
of lower plasma metanephrine levels in patients compared
with matched controls both at baseline and after obtaining
normoglycemia in either group. In contrast, plasma levels of
epinephrine, norepinephrine, or normetanephrine were
comparable between patients and controls at baseline and
throughout normoglycemia. A finding that has not been
documented previously is that in addition to the reduced
responses of plasma epinephrine and norepinephrine to hy-
poglycemia, plasma metanephrine levels increased signifi-
cantly less during hypoglycemia in diabetic patients than in
controls. However, the hypoglycemia-induced increase in
plasma metanephrine calculated as a percentage of the in-
crease in plasma epinephrine was identical in patients and
controls, suggesting similar peripheral (extraadrenal) con-
version of epinephrine to metanephrine.
In humans, over 90% of plasmametanephrine is produced
from epinephrine leaking from storage vesicles into the cy-
toplasm of chromaffin cells (23). This conversion is catalyzed
by intracytoplasmatic COMT. Because metanephrine is con-
tinuously released into the bloodstream, reduced plasma
metanephrine levels reflect reduced adrenomedullary stor-
age of epinephrine (21), which, in turn, indicates a reduced
capacity to secrete epinephrine. Our findings of a reduced
adrenomedullary secretory capacitymay help to explain pre-
vious observations of reduced adrenergic responses to ex-
ercise tests in well controlled diabetic patients, i.e. patients
with probable impaired counterregulatory function (15, 16).
Because hypoglycemia is one of the most profound stimuli
of epinephrine secretion, a reduced capacity to secrete epi-
nephrine is likely to be clinically relevant. However, the
FIG. 1. Mean (SEM) increases in plasma epinephrine and meta-
nephrine (top) and in plasma norepinephrine and normetanephrine
(bottom) in response to hypoglycemia. In both patients and controls,
the increase in plasma metanephrine was 6.7% that of plasma epi-
nephrine (P  NS). *, P  0.05; **, P  0.001 (higher plasma con-
centration vs. that in diabetic patients).






Baseline 0.22  0.03 0.19  0.03 NS
Normoglycemia (5.0 mmol/liter) 0.31  0.05 0.22  0.03 NS
Hypoglycemia (2.5 mmol/liter) 2.49  0.29a 7.60  0.87a 0.0001
Metanephrine (pmol/liter)
Baseline 0.18  0.01 0.24  0.02 0.012
Normoglycemia (5.0 mmol/liter) 0.16  0.01 0.20  0.01b 0.019
Hypoglycemia (2.5 mmol/liter) 0.34  0.03a 0.69  0.05a 0.0001
Norepinephrine (nmol/liter)
Baseline 0.76  0.11 0.68  0.09 NS
Normoglycemia (5.0 mmol/liter) 1.15  0.12b 0.90  0.07b NS
Hypoglycemia (2.5 mmol/liter) 1.80  0.21a 2.92  0.55a 0.005
Normetanephrine (pmol/liter)
Baseline 0.16  0.01 0.20  0.02 NS
Normoglycemia (5.0 mmol/liter) 0.17  0.01 0.16  0.01 NS
Hypoglycemia (2.5 mmol/liter) 0.25  0.02a 0.26  0.03a NS
Data are the mean  SEM. P values given denote differences between patients and controls. To convert plasma values for epinephrine and
norepinephrine to pg/ml, multiply by 183.2 and 169.2, respectively; to convert plasma values for metanephrine and normetanephrine to pg/ml,
divide by 5.08 and 5.46, respectively.
a P  0.01 for trend from baseline (by ANOVA).
b P  0.01 vs. baseline.
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finding of 25% lower plasma metanephrine levels in the
diabetic patients, which is quantitatively less than the im-
paired epinephrine response to hypoglycemia, suggests that
it is an additive component to the previously described re-
setting of the glycemic threshold value (2).
Under hypoglycemic conditions, plasma levels of meta-
nephrine increased in both patients and controls. This in-
crease in plasma metanephrine levels above baseline results
from the metabolism of elevated epinephrine levels either
after reuptake by the adrenals or by extraadrenal conversion,
both of which are catalyzed by COMT (22, 29). Because
hypoglycemia induced a lower epinephrine response in the
diabetic patients, our observation of a blunted increase in
plasma metanephrine during hypoglycemia was not unex-
pected. To assess whether an impairment in the metabolism
of epinephrine contributed to the blunted increase in plasma
metanephrine, we calculated the absolute change in plasma
metanephrine as a percentage of the absolute change in
plasma epinephrine induced by hypoglycemia. The increase
in plasma metanephrine relative to the increase in plasma
epinephrine levels was identical in patients and controls,
whichmatches values reported previously (22) and indicates
similar rates of metabolism and similar COMT activity in
patients and controls, at least under hypoglycemic condi-
tions. This is important because it makes it highly unlikely
that the lower plasma metanephrine levels in diabetic pa-
tients at baseline were the result of reduced COMT activity
within the adrenalmedulla, as has been suggested by studies
in liver homogenates from hyperglycemic streptozotocin-
induced diabetic rats (24). It also challenges the usefulness of
the M/E ratio as a surrogate marker for COMT activity (24).
It seems unlikely that our findings are explained by dia-
betic autonomic neuropathy. First of all, all patients had
normal responses to cardiovascular reflex tests (26). Sec-
ondly, the normal basal plasma epinephrine levels in the
diabetic patients argue against clinically relevant autonomic
neuropathy. As adrenomedullary cells secrete their content
directly into the circulation upon stimulation, basal plasma
epinephrine levels generally reflect basal neuronal outflow to
the adrenal medulla (21), which explains findings of reduced
plasma epinephrine levels in patients with diabetic auto-
nomic neuropathy (30–32). Finally, the normal plasma nor-
epinephrine levels at baseline and the normal response to
hyperinsulinemia (during clamped normoglycemia) further
support the idea that autonomic nervous function was not
substantially impaired.
Limitations of our study concern the small sample size and
the indirect nature of our method to assess adrenomedullary
epinephrine content and secretory capacity. Comparing ad-
renomedullary secretory capacity between diabetic patients
and controls directly would require a stimulus of adreno-
medullary epinephrine secretion other than hypoglycemia
that is at least as profound. However, such a stimulus is
unavailable for in vivo studies in humans. Another limitation
is that it cannot be determined from our data whether the
reduced plasma metanephrine levels in diabetic patients re-
flect a temporal depletion of adrenal stores or a structural loss
of adrenal mass. Because hypoglycemia has been reported to
suppress the adrenergic response to subsequent exercise (14),
temporal exhaustion of adrenal stores seems a plausible phe-
nomenon in patients with type 1 diabetes. In rats, recurrent
hypoglycemia was found to both suppress the epinephrine
response to subsequent hypoglycemia and to chronically
enhance adrenal sympathetic tone. This observation indi-
cates that the defect in epinephrine release occurred as a
result of or at least persisted despite maximal stimulation,
both ofwhich are compatiblewith depletion of adrenal stores
(33). It could be hypothesized that repeated hypoglycemia-
induced exhaustion of adrenal storesmay eventually become
a structural defect. A structural loss of adrenal mass could
explain why epinephrine responses to exercise tests remain
lower in diabetic patients despite scrupulous avoidance of
hypoglycemia (15, 16), and why hypoglycemia prevention
programs do not completely restore the impaired epineph-
rine response to hypoglycemia (10).
In conclusion, our study shows that diabetic patients with
established (hypoglycemia-induced) counterregulatory fail-
ure have low plasma metanephrine levels compared with
nondiabetic controls. Assuming similar metabolic rates
within the adrenal medulla, the lower plasma metanephrine
levels reflect reduced epinephrine storage and reduced ad-
renomedullary secretory capacity. To what extent a reduced
adrenomedullary capacity contributes to the failure to se-
crete sufficient amounts of epinephrine under hypoglycemic
conditions cannot be derived from the present study, but
assuming that hypoglycemia requires the maximum adrenal
reserve, it is likely to be clinically relevant.
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